Thymosin alpha 1 peptide(cov npe nrov npe: Thymalfasin/Zadaxin) yog luv peptide immunomodulator muab los ntawm prothymosin alpha. Nws ua los ntawm kev txhim kho, rov kho dua, thiab kho cov tshuaj tiv thaiv kab mob zoo; Cov teebmeem tseem ceeb suav nrog kev txhawb nqa dendritic cell maturation, tsav T-cell polarization thiab kev ua haujlwm rov qab los, txhawb nqa cov neeg tua neeg ntawm tes (NK) kev ua haujlwm, thiab ua kom zoo dua cytokine tes hauj lwm cuam tshuam rau kev tiv thaiv kab mob thiab tshuaj tiv thaiv kab mob. Clinically, feem ntau cov ntawv thov kev kawm yog adjunctive therapy rau cov kab mob siab B ntev, kev tiv thaiv kab mob hauv lub xeev ntawm kev tiv thaiv kab mob, thiab siv raws li kev tiv thaiv kab mob rau qee yam kev kho mob lossis tshuaj tiv thaiv.
Shaanxi Medibridge tau siv sijhawm 14 xyoo los muab cov ntaub ntawv tshawb fawb qib peptide rau cov chaw soj nstuam thoob ntiaj teb, tsim kev txawj ntse hauv kev sib txuas, kev ua kom huv, thiab kev tswj kom zoo. Peb muab Thymosin alpha 1 txog li 99.62% purity, txhawb nqa los ntawm HPLC/LC-MS cov ntaub ntawv thiab tag nrho COAs. Ntau ntau yog sib xws los ntawm grams mus rau ntau-kilogram xaj.
COA
|
|
||
|
Khoom npe |
CAS Nr |
Batch Number |
|
Thymosin alpha 1 peptide |
62304-98-7 |
MB2509081549 |
|
Hnub tim tsim khoom |
Hnub Soj Ntsuam |
Hnub Kawg |
|
2025-09-08 |
2025-09-09 |
2027-09-07 |
|
Qauv Qty Base |
Ntim |
Txoj Kev Xeem |
|
6.32 KWG |
10 Gs/BOTTLE |
HPLC |
|
Yam khoom |
Txuj |
Cov txiaj ntsig |
|
Purity |
Ntau dua lossis sib npaug li 98% |
99.62% |
|
Peptide Assay |
Ntau dua lossis sib npaug li 80% |
88.53% |
|
Loj Spectrum |
3108.28 |
3108.28 |
|
Solubility |
Soluble hauv dej |
Ua raws |
|
Clarity thiab xim ntawm kev daws |
Ntshiab thiab tsis muaj xim |
Ua raws |
|
Sodium ntsev |
<5.0% |
1.15% |
|
Dej |
Tsawg dua lossis sib npaug li 7.0% |
3.51% |
|
Residual Solvent: |
||
|
Methanol |
Tsawg dua lossis sib npaug li 0.3% |
Ua raws |
|
Isopropanol |
Tsawg dua los yog sib npaug li 0.5% |
0.158% |
|
Cov tshuaj acetonitrile |
Tsawg dua lossis sib npaug li 0.041% |
0.019% |
|
Methylene Chloride |
Tsawg dua lossis sib npaug li 0.06% |
0.028% |
|
N,N{0}}Dimethylformamide |
Tsawg dua lossis sib npaug li 0.088% |
Ua raws |
|
Triethylamine |
Tsawg dua lossis sib npaug li 0.032% |
Ua raws |
|
Tert -butyl methyl ether |
Tsawg dua los yog sib npaug li 0.5% |
0.152% |
|
Endotoxin |
Tsawg dua lossis sib npaug li 0.5 EU / mg |
Ua raws |
|
Microbial txwv |
Tag nrho cov kab mob aerobic<100 CFU/g Tag nrho cov poov xab & pwm<50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Cia |
Khaws rau hauv qhov chaw tsaus thiab txias qhuav (-20 txog 8 degree) |
|
|
Xaus |
Cov batch ua raws li IN-HOUSE tus qauv |
|
|
|
||
Specification (rau kev tshawb fawb siv nkaus xwb)
Peb qhov zoo
1.Ultra-high purity: mus txog 99.62% los ntawm kev txheeb xyuas HPLC; Kev lees paub tus kheej los ntawm LC-MS, muab nrog CoA tag nrho.
2.Kev tshawb fawb-qib zoo: qis endotoxin thiab bioburden kuaj los txhawb kev tshawb fawb hauv vitro thiab in-vivo.
3.Consistent kev ua tau zoo: tswj synthesis thiab purification xa nruj heev-rau-ntau qhov sib txawv.
4.Practical hom: lyophilized hmoov, txheem pob los ntawm milligrams mus rau multi-gram.
5.Kev xaiv kev cai: aliquoting thiab counter-ion pauv (xws li, acetate) muaj nyob rau ntawm kev thov.
6.Responsive service: ceev ceev cov sij hawm thiab kev pab cuam rau kev teeb tsa raws tu qauv thiab kev ntsuam xyuas teeb meem.
|
Daim ntawv |
Qauv Order |
Specification |
|
Cov hmoov nyoos |
1 g |
Purity yog NLT 99.62% |
|
Vials |
10 vials |
3ml / 5ml / 7ml / 15ml vials thiab lwm yam. |
Khoom Description
Dendritic cells (DCs) thiab innate immunity
a. Txhawb nqa DC maturation thiab upregulation ntawm co-stimulatory molecules (CD80/CD86, HLA-DR), txhim kho antigen kev nthuav qhia thiab cross-presentation.
b. Modulates tus xov tooj zoo li receptor (TLR) txoj hauv kev- feem ntau tshwj xeeb tshaj yog TLR2 / TLR9 axis- ua kom nrov nrov hauv qab MyD88 / NF-κB taw qhia thiab ntsuas hom I interferons thiab IL-12.
T hlwb thiab yoog raws kev tiv thaiv
a. Tsav cov lus teb Th1-skewed (IFN- ↑, IL-2↑); Hauv qee cov ntsiab lus txo cov Th2/immunosuppressive yam (xws li, IL-4/IL-10), kho Treg/effector T-cell imbalance.
b. Txhim kho CD8+ cytotoxic T-cell muaj nuj nqi nrog ib qho kev hloov mus rau kev thim rov qab (cov ntaub ntawv qhia txog granzyme / perforin ntau ntxiv).
NK/antiviral thiab antitumor teebmeem
a. Ua kom NK-cell cytotoxicity thiab lub hom phiaj tshwj xeeb, tsis ncaj qha kev txhim kho kev paub txog MHC-I phenotypes.
b. Tsis muaj kev tiv thaiv kab mob ncaj qha; Nws cov nyhuv "antiviral" tshwm sim thawj zaug los ntawm kev tiv thaiv kab mob thiab txhim kho kev tshem tawm.
Immune homeostasis
Hauv cov xeev immunocompromised (post-chemotherapy, immunosenescence, los yog tom qab kis mob hnyav), pab kho cov lymphocyte profiles thiab ua haujlwm; siv ceev faj hauv kev teeb tsa autoimmune kom tsis txhob ua kom dhau.
Cov ntawv thov kev kho mob thiab cov ntaub ntawv pov thawj (Kev Tshawb Fawb / Kev Tshawb Fawb Kev Tshawb Fawb)
1. Mob hnyav thiab mob sepsis
Tsis ntev los no multicenter RCTs thiab meta- kev tshuaj ntsuam sib sau qhia tiasThymosin alpha 1 peptidetej zaum yuav txo tau 28-hnub kev tuag tag nrho, tab sis cov txiaj ntsig tau txo qis hauv cov pab pawg zoo dua thiab ntau pawg hauv pawg- qhia txog kev nkag siab zoo rau kev sim siab thiab cov pej xeem sib txawv. Ib qho kev hloov kho meta-analysis ntawm 11 RCTs (n≈1,927) tau pom qhov txo qis hauv 28-hnub kev tuag (OR≈0.73, 95% CI 0.59–0.90), tab sis kev soj ntsuam ua ntu zus tsis ncav cuag cov ntaub ntawv loj. Hauv kev sim ua kom zoo, cov nyhuv me me (OR≈0.82, P=0.09), thiab hauv ntau qhov kev tshawb fawb nws tsis tseem ceeb (OR≈0.86, P=0.20). Qhov loj tshaj ob-dig muag, multicenter theem III RCT (TESTS; n=1,106) tsis tau txhim kho kev tuag lossis cov txiaj ntsig loj tag nrho, txawm hais tias kev tshawb nrhiav pom tshwm sim hauv cov pab pawg xws li cov neeg laus thiab cov neeg mob ntshav qab zib, qhia txog kev xav tau ntawm tus kheej, biomarker-guided strategies.
Mechanism-aligned intermediates: Ntau RCTs qhia txog kev nce hauv peripheral monocyte mHLA-DR, rov qab los ntawm T-cell compartments, thiab txo qis hauv APACHE II cov qhab nia, thaum SOFA qhov sib txawv tsuas yog txwv thiab cov txiaj ntsig tsis sib xws hauv cov kev tshawb fawb.
Kev Kawm Txuj Ci: Cov ntaub ntawv pov thawj tam sim no nyiam cov qauv kev sim uas ua kom muaj txiaj ntsig zoo rau cov lus teb thiab siv cov tshuaj tiv thaiv kab mob biomarkers- xws li qis mHLA-DR lossis T-cell qaug zog profile- txhawm rau txo cov nyhuv dilution los ntawm pawg neeg sib txawv.
Mob hnyav pancreatitis (SAP)
Ib qho kev tshuaj xyuas 2025 thiab meta-analysis ntawm tsib RCTs (n=706) pom tias T 1 tau nce CD4+ feem ntau (MD≈+4.53%) thiab CD4/CD8 piv (MD≈+0.42), txo CRP (tsawg koob 1.6 mg/hnub pawg kab mob ntxiv 30-a MD≈) zuag qhia tag nrho (RR≈0.56; kab mob ntshav RR≈0.60; intra-abdominal infection RR≈0.38). Kev nyob ntev tsis hloov pauv, thaum APACHE II cov qhab nia poob qis (MD≈−1.52).
Multicenter, ob-dig muag RCTs txhawb nqa qhov ua tau ntawm kev tiv thaiv kev tiv thaiv kab mob hauv kev pheej hmoo siab SAP, tab sis cov koob tshuaj zoo tshaj plaws, lub sijhawm, thiab cov neeg tau txais txiaj ntsig cov ntaub ntawv tseem raug txhais.
Kev kawm coj mus kawm: qhov txo qis ntawm cov teeb meem sib kis yuav ua raws li cov saw ntawm CD4+ rov kho dua, rov ntsuas qhov mob, thiab txhim kho kev cuam tshuam / tshem tawm kev ua haujlwm. Kev koom ua ke nrog kev noj zaub mov, tswj kev kis kab mob, thiab kev cuam tshuam tsawg kawg nkaus yog pom zoo kom paub txog tus nqi kho mob.
Methodology thiab Kev Tshawb Fawb Yav Tom Ntej
Cov pov thawj hierarchy
Ib qho kev sib cais tsis tu ncua: me me, ib qho kev sim hauv ib qho kev sim feem ntau qhia tau txiaj ntsig, thaum loj, ntau qhov kev tshawb fawb ntau qhov zoo sib xws rau cov txiaj ntsig nruab nrab. Kev soj ntsuam ua ntu zus qhia tau hais tias cov ntaub ntawv sib sau loj tseem tsis txaus, yog li txhua qhov kev txiav txim siab yuav tsum suav tias yog ib ntus.
Population stratification
Kev tshawb nrhiav pawg pab pawg tau raug sau tseg hauv cov neeg mob uas muaj mob qog noj ntshav, ntshav qab zib, lossis kab mob plawv, nrog rau qhov tseeb txij li qis mus rau nruab nrab. Cov kev tshawb pom no txhawb nqa qhov ua tau ntawm qhov tseeb-immunology lub tswv yim.
Kev sim tsim cov lus pom zoo
1.Base kev tsim nyog ntawm kev tiv thaiv kab mob phenotypes-xws li, tsis tshua muaj monocyte HLA-DR, CD4/CD8 imbalance, los yog cov cim ntawm T-cell qaug zog- tsis yog kev kuaj mob ib leeg.
2.Siv cov txheej txheem sib xyaw ua ke uas suav nrog kev ntsuas tshuaj lom neeg thiab cov chaw kho mob, thiab suav nrog kev soj ntsuam ntev ntev (90 hnub thiab 6 lub hlis).
3.Employ add-on designs atop standard care, with preplanned interaction analysis for combinations with interferon/antivirals, ICIs, or immunonutrition.
FAQ
Q: Dab tsi yog thymosin alpha 1 siv rau?
A: Kev tsom xam tam sim no: biomarker-enriched cohorts (tsawg mHLA-DR, CD4/CD8 imbalance, T-cell qaug zog).
Q: Cov kev phiv ntawm thymosin alpha 1 peptide yog dab tsi?
A: Feem ntau me me: txhaj tshuaj-qhov chaw erythema / mob thiab cov tsos mob zoo li mob khaub thuas; qee zaum qaug zog / mob taub hau. Tsis tshua muaj kev pheej hmoo: autoimmune flare lossis graft rejection- saib xyuas cov lymphocyte subsets thiab daim siab enzymes hauv kev tshawb fawb.
Q: thymosin alpha 1 puas tuaj yeem pab nrog cov kab mob autoimmune?
A: Cov ntaub ntawv pov thawj tsis txaus. Muab nws lub peev xwm Th1-skewing, nws tuaj yeem ua rau qee yam mob autoimmune; txwv kev siv rau kev sim tshuaj raws li tus kws saib xyuas tshwj xeeb nrog kev saib xyuas kab mob-kev ua haujlwm.
Q: Koj puas yog tus neeg muag khoom peptide?
A: Yog lawm, peb yog lub Hoobkas tshwj xeeb hauv kev tsim khoom thiab kev muag khoom ntawm peptides thiab APIs.
Q: Koj puas tuaj yeem muab OEM / ODM?
A: Tau kawg, peb tuaj yeem tsis tsuas yog muab cov kev pabcuam no, tab sis kuj muab cov kev daws teeb meem customized.
Q: Koj puas lav qhov kev xa khoom zoo?
A: Qhov no yog lub hauv paus ntawm peb cov kev pabcuam lav. Peb yuav xyuas kom koj tau txais koj cov khoom nyob rau hauv zoo meej. Txwv tsis pub, peb yuav muab cov khoom xa rov qab / cov nyiaj rov qab tsis muaj xwm txheej.
Cim npe nrov: Tuam Tshoj thymosin alpha 1 peptide manufacturers, lwm tus neeg, Hoobkas
